These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 33069214)

  • 1. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
    Ailani J; Andrews JS; Rettiganti M; Nicholson RA
    J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
    Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
    J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis.
    Ailani J; Andrews JS; Tockhorn-Heidenreich A; Wenzel R; Rettiganti M
    Adv Ther; 2022 Oct; 39(10):4544-4555. PubMed ID: 35930126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
    Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
    J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
    Varnado OJ; Ye W; Mi X; Burge R; Hall J
    J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
    Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
    Tepper SJ; Dong Y; Vincent M; Wietecha LA
    Headache; 2023; 63(10):1380-1390. PubMed ID: 37132481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.
    Stauffer VL; Turner I; Kemmer P; Kielbasa W; Day K; Port M; Quinlan T; Camporeale A
    J Headache Pain; 2020 Jun; 21(1):79. PubMed ID: 32576229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
    Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
    Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm.
    Citrome L; Sánchez Del Rio M; Dong Y; Nichols RM; Tockhorn-Heidenreich A; Foster SA; Stauffer VL
    Adv Ther; 2021 Aug; 38(8):4442-4460. PubMed ID: 34264500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis.
    Pozo-Rosich P; Samaan KH; Schwedt TJ; Nicholson RA; Rettiganti M; Pearlman EM
    Adv Ther; 2021 Jun; 38(6):3154-3165. PubMed ID: 33950375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
    Dodick DW; Doty EG; Aurora SK; Ruff DD; Stauffer VL; Jedynak J; Dong Y; Pearlman EM
    Cephalalgia; 2021 Mar; 41(3):340-352. PubMed ID: 33143451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials.
    Kuruppu DK; North JM; Kovacik AJ; Dong Y; Pearlman EM; Hutchinson SL
    Adv Ther; 2021 Mar; 38(3):1614-1626. PubMed ID: 33544305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.
    Lipton RB; Buse DC; Sandoe CH; Ford JH; Hand AL; Jedynak JP; Port MD; Detke HC
    Headache; 2023 May; 63(5):683-691. PubMed ID: 36797223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.